Previous Close | 15.20 |
Open | 38.00 |
Bid | 15.10 x 0 |
Ask | 15.60 x 0 |
Day's Range | 15.00 - 15.80 |
52 Week Range | 10.80 - 42.80 |
Volume | |
Avg. Volume | 179 |
Market Cap | 726.438M |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.45 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 44.25 |
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ...